# What Drugs Are Defined as Schedule 3 as Trump Reclassifies Cannabis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/schedule-3-drug-classification-cannabis-reclassification-trump/ > **Published:** 2026-04-24T19:06:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:11:10-04:00 > **Clinical Summary:** Explore the schedule 3 drug classification and how Trump's cannabis reclassification impacts medical research and federal policy. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyResearchFederal Regulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Drug Scheduling Why This Matters Schedule III reclassification would fundamentally alter [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) capabilities and clinical access pathways. This represents the most significant federal policy shift for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) since the Controlled Substances Act, potentially enabling standardized research protocols and institutional participation that current Schedule I status prohibits. Clinical Summary Cannabis reclassification from Schedule I to Schedule III would place it alongside substances like ketamine and testosterone – controlled but with accepted medical use. This change would remove research barriers that currently require DEA manufacturing licenses, enable institutional review board approvals at academic centers, and potentially allow interstate medical cannabis commerce. However, it would not federally legalize recreational use or override existing state medical cannabis frameworks. Dr. Caplan’s Take “This policy shift could finally unlock the rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) we desperately need to establish dosing protocols and safety profiles. After treating hundreds of thousands of patients with limited research foundation, having FDA-supervised studies would transform cannabis from experiential medicine to evidence-based practice.” Clinical Perspective 🧠 Clinicians should prepare for increased institutional support for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and potentially new FDA-approved cannabis medications. Patient care protocols may evolve significantly as standardized products and dosing guidelines emerge from enhanced research capabilities. This change addresses regulatory barriers, not immediate clinical practice, so current state-legal medical cannabis programs remain the primary access pathway. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20What%20drugs%20are%20defined%20as%20%E2%80%98schedule%203%E2%80%99%20as%20Trump%20reclassifies%20cannabis%20%E2%80%93%20LADbible%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fwhat-drugs-are-defined-as-schedule-3-as-trump-reclassifies-cannabis-ladbible%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fwhat-drugs-are-defined-as-schedule-3-as-trump-reclassifies-cannabis-ladbible%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20What%20drugs%20are%20defined%20as%20%E2%80%98schedule%203%E2%80%99%20as%20Trump%20reclassifies%20cannabis%20%E2%80%93%20LADbible%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fwhat-drugs-are-defined-as-schedule-3-as-trump-reclassifies-cannabis-ladbible%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.ladbible.com/news/us-news/donald-trump-medical-cannabis-reclassify-todd-blanche-975930-20260424](https://www.ladbible.com/news/us-news/donald-trump-medical-cannabis-reclassify-todd-blanche-975930-20260424) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related topics does this article cover?](#What_type_of_cannabis-related_topics_does_this_article_cover) - [Why is this article marked as “New”?](#Why_is_this_article_marked_as_8220New8221) - [What does “Notable Clinical Interest” mean for healthcare providers?](#What_does_8220Notable_Clinical_Interest8221_mean_for_healthcare_providers) - [How does federal regulation impact medical cannabis practice?](#How_does_federal_regulation_impact_medical_cannabis_practice) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related topics does this article cover? Based on the categorization tags, this article covers policy developments, research findings, federal regulation updates, and medical cannabis topics. These areas represent key aspects of the evolving cannabis landscape that impact clinical practice. #### Why is this article marked as “New”? The “New” designation indicates this is recently published or updated content. This helps healthcare professionals stay current with the latest developments in cannabis policy and research that may affect their practice. #### What does “Notable Clinical Interest” mean for healthcare providers? Notable Clinical Interest suggests that while this information may not require immediate action, it represents important developments worth tracking. Healthcare providers should be aware of these emerging trends as they may influence future clinical guidelines or patient care protocols. #### How does federal regulation impact medical cannabis practice? Federal regulation changes can significantly affect how healthcare providers can recommend, prescribe, or discuss cannabis treatments with patients. Understanding these regulatory developments is crucial for maintaining compliant and effective clinical practice in states with medical cannabis programs. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Administration Moves to Reclassify Marijuana as Schedule III Drug | National News](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) Detailed coverage of the Trump administration's efforts to reclassify marijuana as a Schedule III drug, highlighting policy implications. [Read More](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) [DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) Insights into DOJ's recent moves to ease cannabis restrictions and the potential shift toward rescheduling cannabis federally. [Explore Details](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) [Trump Administration to Reclassify Medical Marijuana Restrictions, Expanding Research Potential](https://cedclinic.com/trump-administration-cannabis-research-expansion/) An analysis of how the Trump administration's reclassification could expand [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) research opportunities. [Learn More](https://cedclinic.com/trump-administration-cannabis-research-expansion/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).